Cochlear

Cochlear Limited is a mission-driven medical device leader with a singular focus on treating moderate-to-profound hearing loss. The company has achieved a dominant global market position, serving over 750,000 recipients with its clinically validated, life-changing implant systems. Its strategy is built on continuous innovation within its core Nucleus and bone conduction platforms, deep clinical and customer support networks, and leveraging its installed base through recurring revenue from sound processor upgrades. This approach has established a powerful, durable brand and a sustainable financial model.

Cochlear's core technology is based on proprietary implantable neurostimulation platforms: the Nucleus system for cochlear implants that electrically stimulate the auditory nerve, and active/passive bone conduction systems (Osia and Baha) that transmit sound via mechanical vibrations through the skull bone.